Resources

It has been known for a long time that excess weight shortens human lifespan. The body mass index (BMI) is a strong predictor of overall mortality both above and below the apparent optimum of about 22.5 -25 kg/m2.

Heart bypass surgery may be less dangerous for older patients with diabetes than angioplasty, researchers reported. Patients with diabetes were 30 percent less likely to die if they got the…

Blood pressure and cholesterol need to be controlled more aggressively, a new study suggests.

Delivering a gene called neurogenin3 into the livers of diabetic mice activates adult stem cells that promote steady insulin production, say researchers. 

Three simple clinical tests could help identify a large group of patients with elevated heart attack risk who aren’t reflected in traditional risk scores, researchers said.

Diabetic patients with atrial fibrillation (AF) are at a significantly greater risk of adverse clinical outcomes than those without AF, a new analysis has shown. Compared with those without the rhythm disorder, diabetic patients with AF are more likely to die from all or cardiovascular causes, as well as have …

Adding to evidence linking hyperglycemia and mortality in acute myocardial infarction (AMI) patients, a new observational study indicates that AMI patients with hyperglycemia at the time of hospital admission whose glucose levels fall to normal ranges during their hospital stay are more likely to survive.

The results are in and both coffee and chocolate have health benefits, but to what extent?

I was reviewing some new studies on the use of insulin this past week and every study seemed to use HOMA values. Homeostatic model assessment (HOMA) was first used in 1985 and was derived mathematically by looking at the interaction between beta-cell function and insulin resistance of normoglycemic patients. Alexander …

A U.S. Food and Drug Administration panel will review two proposed drugs to treat Type 2 diabetes this April. According to a meeting notice posted on the FDA’s website Monday, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will discuss Bristol-Myers Squibb’s saxagliptin tablets on April 1 and Novo Nordisk.’s liraglutide …